ENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020
March 16, 2020 16:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...
Entera Bio Announces the Completion of $14.3 million Private Placement
December 18, 2019 16:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased...
Entera Announces Closing of Private Placement
December 11, 2019 17:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed...
Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update
November 21, 2019 07:00 ET
|
Entera Bio Ltd.
Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism...
Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer
November 21, 2019 07:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as...
Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019
November 07, 2019 16:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September...
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
September 23, 2019 08:00 ET
|
Entera Bio Ltd.
Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual MeetingData suggest favorable...
Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 19, 2019 08:00 ET
|
Entera Bio Ltd.
JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present...
Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update
August 20, 2019 07:00 ET
|
Entera Bio Ltd.
Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented...